BioCryst Pharmaceuticals IncBCRX

BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema ('HAE') and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO ® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for a range of rare.

biocryst.com